Generalized Pustular Psoriasis (GPP) Market Outlook

Thelansis’s “Generalized Pustular Psoriasis (GPP) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2025 To 2035” covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Generalized Pustular Psoriasis treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Generalized Pustular Psoriasis (GPP) Overview

Generalized pustular psoriasis (GPP) is a rare, potentially life-threatening autoinflammatory skin disorder characterised by widespread sterile neutrophilic pustulation on erythematous skin, distinct from plaque psoriasis in pathophysiology, genetics, and management. Loss-of-function mutations in IL36RN encoding the IL-36 receptor antagonist are the most prevalent genetic driver, with additional mutations in CARD14, AP1S3, and MPO identified in subsets, collectively resulting in unchecked IL-36 pathway hyperactivation and massive neutrophilic skin inflammation. Flares may be triggered by infection, pregnancy, medication withdrawal including systemic corticosteroids, and stress. Patients present acutely with widespread erythema, sheets of coalescing sterile pustules, fever, and systemic inflammatory response, with severe flares complicated by sepsis, hepatic dysfunction, hypoalbuminaemia, and cardiovascular compromise. Diagnosis is clinical and histopathological, supported by elevated inflammatory markers and neutrophilia, with genetic testing informing long-term management. Spesolimab, a first-in-class IL-36 receptor antagonist monoclonal antibody, is the landmark approved therapy for acute GPP flares, delivering rapid pustular clearance; its subcutaneous formulation is additionally approved for maintenance therapy preventing flare recurrence. Imsidolimab, a second IL-36 receptor antagonist with robust Phase III GEMINI trial data, is currently under active FDA regulatory review with a PDUFA date in late 2026, representing a highly anticipated near-term addition to the GPP armamentarium. Prognosis varies with flare severity and genetic background; multidisciplinary dermatological care, trigger avoidance, and patient-centred monitoring are integral to long-term management.

Geography coverage:

G8 (United States, EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)

Insights driven by robust research, including:

• In-depth interviews with leading KOLs and payers
• Physician surveys
• RWE analysis for claims and EHR datasets
• Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

• Detailed Report (PDF)
• Market Forecast Model (MS Excel-based automated dashboard)
• Epidemiology (MS Excel; interactive tool)
• Executive Insights (PowerPoint presentation)
• Others: regular updates, customizations, consultant support

*As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

• 10-year market forecast (2025–2035)
• Bottom-up patient-based market forecasts validated through the top-down sales methodology
• Covers clinically and commercially-relevant patient populations/ line of therapies
• Annualized drug-level sales and patient share projections
• Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
• Detailed methodology/sources & assumptions
• Graphical and tabular outputs
• Users can customize the model based on requirements

Key business questions answered:

• How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
• How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
• What is the 10-year market outlook for sales and patient share?
• Which events will have the greatest impact on the market’s trajectory?
• What insights do interviewed experts provide on current and emerging treatments?
• Which pipeline products show the most promise, and what is their potential for launch and future positioning?
• What are the key unmet needs and KOL expectations for target profiles?
• What key regulatory and payer requirements must be met to secure drug approval and favorable market access?
• and more…

1. Key Findings and Analyst Commentary

• Key trends: market snapshots, SWOT analysis, commercial benefits and risk, etc..

2. Disease Context

• Disease definition, classification, etiology and pathophysiology, drug targets,etc.

3. Epidemiology

• Key takeaways
• Incidence / Prevalence
• Diagnosed and Drug-Treated populations
• Comorbidities
• Other relevant patient segments

4. Market Size and Forecast

• Key takeaways
• Market drivers and constraints
• Drug-class specific trends
• Country-specific trends

5. Competitive Landscape

• Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies – profiles and KOL insights
• Emerging therapies
  • Key takeaways
  • Notable late-phase emerging therapies – profiles, launch expectations, KOL insights
  • Notable early-phase pipeline

6. Unmet Need and TPP Analysis

• Top unmet needs and future attainment by emerging therapies
• TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)